Skip to main content
SpringerLink
Log in

Skin autofluorescence is elevated in acute myocardial infarction and is associated with the one-year incidence of major adverse cardiac events

  • Original article
  • Published:
Netherlands Heart Journal Aims and scope Submit manuscript

Abstract

Background.ST-elevation myocardial infarction (STEMI) is associated with increased inflammation and oxidative stress, enhancing the formation of advanced glycation endproducts (AGEs). These encompass a characteristic fluorescence pattern, which can be non-invasively measured as skin autofluorescence (AF). In this study we investigate whether skin AF is elevated in STEMI, its association with inflammatory and glycaemic stress and its predictive value for future events.

Methods.Skin AF was measured in 88 STEMI patients (mean age 64±13 years) within 72 hours and around six months after discharge, in 81 stable coronary artery disease (sCAD) patients (64±10 years), and in 32 healthy controls (63±11 years). The cumulative one-year incidence of all-cause mortality and hospitalisation for myocardial infarction or heart failure was documented.

Results.Skin AF was significantly higher in STEMI compared with sCAD and controls, irrespective of confounders, and was associated with HbA1c and C-reactive protein. Skin AF decreased significantly in STEMI patients, when measured >200 days after discharge. In STEMI patients, skin AF above the median was predictive of future events (hazard ratio 11.6, 95% CI 1.5 to 90.8, p=0.019).

Conclusion.Skin AF is elevated in STEMI, is associated with inflammation and glycaemic stress, and predicts future major adverse cardiac events. (Neth Heart J 2009;17:162–8.)

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Stocker R, Keaney J. Role of oxidative modifications in atherosclerosis. Physiol Rev 2004;84:1381–478.

    Google Scholar 

  2. Walter M, Jacob R, Jeffers B, Ghadanfar M, Preston G, Buch J, et al. Serum levels of thiobarbituric acid reactive substances predict cardiovascular events in patients with stable coronary artery disease: a longitudinal analysis of the PREVENT study. J Am Coll Cardiol 2004;44:1996–2002.

    Google Scholar 

  3. Heitzer T, Schlinzig T, Krohn K, Meinertz T, Munzel T. Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease. Circulation 2001;104: 2673–8.

    Google Scholar 

  4. Holvoet P, Collen D, Van de Werf F. Malondialdehyde-modified LDL as a marker of acute coronary syndromes. JAMA 1999;281: 1718–21.

    Google Scholar 

  5. Shimomura H, Ogawa H, Takazoe K, Soejima H, Miyamoto S, Sakamoto T, et al. Comparison of urinary biopyrrin levels in acute myocardial infarction (after reperfusion therapy) versus stable angina pectoris and their usefulness in predicting subsequent cardiac events. Am J Cardiol 2002;90:108–111.

    Google Scholar 

  6. Schwedhelm E, Bartling A, Lenzen H, Tsikas D, Maas R, Brummer J, et al. Urinary 8-iso-Prostaglandin F2{alpha} as a risk marker in patients with coronary heart disease: A matched casecontrol study. Circulation 2004; 109:843–8.

    Google Scholar 

  7. Smit A, Lutgers H. The clinical relevance of advanced glycation endproducts (AGE) and recent developments in pharmaceutics to reduce AGE accumulation. Curr Med Chem 2004;11:2767–84.

    Google Scholar 

  8. Baynes JW, Thorpe SR. Glycoxidation and lipoxidation in atherogenesis. Free Radic Biol Med 2000;28:1708–16.

    Google Scholar 

  9. Meerwaldt R, Hartog JW, Graaff R, Huisman RJ, Links TP, den Hollander NC, et al. Skin autofluorescence, a measure of cumulative metabolic stress and advanced glycation end products, predicts mortality in hemodialysis patients. J Am Soc Nephrol 2005;16:3687–93.

    Google Scholar 

  10. Meerwaldt R, Lutgers HL, Links TP, Graaff R, Baynes JW, Gans RO, et al. Skin autofluorescence is a strong predictor of cardiac mortality in diabetes. Diabetes Care 2007;30:107–12.

    Google Scholar 

  11. Mulder DJ, van Haelst PL, Gross S, de LK, Bijzet J, Graaff R, et al. Skin autofluorescence is elevated in patients with stable coronary artery disease and is associated with serum levels of neopterin and the soluble receptor for advanced glycation end products. Atherosclerosis 2007;197:217–23.

  12. Meerwaldt R, Oomen PHN, Links TP, Gans ROB, Smit AJ, Graaff R, et al. Simple non-invasive assessment of advanced glycation endproduct accumulation. Diabetologia 2004;47:1324–30.

    Google Scholar 

  13. Meerwaldt R, Links T, Graaff R, Thorpe SR, Baynes JW, Hartog J, et al. Simple noninvasive measurement of skin autofluorescence. Ann N Y Acad Sci 2005;1043:290–8.

    Google Scholar 

  14. Mulder DJ, van Haelst PL, Graaff R, Smit AJ, Gans RO, Zijlstra F. Skin autofluorescence is an independent marker for acute myocardial infarction. Circulation 2005;112:U427.

    Google Scholar 

  15. Fu MX, Requena JR, Jenkins AJ, Lyons TJ, Baynes JW, Thorpe SR. The advanced glycation end product, Nepsilon-(carboxymethyl) lysine, is a product of both lipid peroxidation and glycoxidation reactions. J Biol Chem 1996;271:9982–6.

    Google Scholar 

  16. Hartog J, de Vries A, Lutgers H, Meerwaldt R, Huisman R, van Son W, et al. Accumulation of advanced glycation end products, measured as skin autofluorescence, in renal disease. Ann N Y Acad Sci 2005;1043:299–307.

    Google Scholar 

  17. Lutgers HL, Graaff R, Links TP, Ubink-Veltmaat LJ, Bilo HJ, Gans RO, et al. Skin autofluorescence as a noninvasive marker of vascular damage in patients with type 2 diabetes. Diabetes Care 2006;29:2654–9.

    Google Scholar 

  18. Meerwaldt R, Graaff R, Links T, Baynes JW, Navis G, Huisman R, et al. Skin autofluorescence, a noninvasive measure of advanced glycation end product accumulation, is a predictor of mortality in hemodialysis patients. Ann N Y Acad Sci 2005;1043:911.

    Google Scholar 

  19. Valgimigli M, Merli E, Malagutti P, Soukhomovskaia O, Cicchitelli G, Macri G, et al. Endothelial dysfunction in acute and chronic coronary syndromes: evidence for a pathogenetic role of oxidative stress. Arch Biochem Biophys 2003;420:255–61.

    Google Scholar 

  20. Horiuchi M, Tsutsui M, Tasaki H, Morishita T, Suda O, Nakata S, et al. Upregulation of vascular extracellular superoxide dismutase in patients with acute coronary syndromes. Arterioscler Thromb Vasc Biol 2004;24:106–11.

    Google Scholar 

  21. Wang XL, Adachi T, Sim AS, Wilcken DEL. Plasma extracellular superoxide dismutase levels in an Australian population with coronary artery disease. Arterioscler Thromb Vasc Biol 1998;18: 1915–21.

    Google Scholar 

  22. Vassalle C, Petrozzi L, Botto N, Andreassi MG, Zucchelli GC. Oxidative stress and its association with coronary artery disease and different atherogenic risk factors. J Intern Med 2004;256:308–15.

    Google Scholar 

  23. Ridker PM, Brown NJ, Vaughan DE, Harrison DG, Mehta JL. Established and emerging plasma biomarkers in the prediction of first atherothrombotic events. Circulation 2004;109:IV6–19.

    Google Scholar 

  24. Kanauchi M, Tsujimoto N, Hashimoto T. Advanced glycation end products in nondiabetic patients with coronary artery disease. Diabetes Care 2001;24:1620.

    Google Scholar 

  25. Kilhovd BK, Juutilainen A, Lehto S, Ronnemaa T, Torjesen PA, Birkeland KI, et al. High serum levels of advanced glycation end products predict increased coronary heart disease mortality in nondiabetic women but not in nondiabetic men: a population-based 18-year follow-up study. Arterioscler Thromb Vasc Biol 2005;25: 815–20.

    Google Scholar 

  26. Bierhaus A, Hofmann MA, Ziegler R, Nawroth PP. AGEs and their interaction with AGE-receptors in vascular disease and diabetes mellitus. I. The AGE concept. Cardiovasc Res 1998;37: 586–600.

    Google Scholar 

  27. Bucciarelli LG, Kaneko M, Ananthakrishnan R, Harja E, Lee LK, Hwang YC, et al. Receptor for advanced-glycation end products: key modulator of myocardial ischemic injury. Circulation 2006; 113:1226–34.

    Google Scholar 

  28. Forbes J, Yee L, Thallas V, Lassila M, Candido R, Jandeleit-Dahm K, et al. Advanced glycation end product interventions reduce diabetes-accelerated atherosclerosis. Diabetes 2004;53:1813–23.

    Google Scholar 

  29. Park L, Raman K, Lee K, Lu Y, Ferran L, Chow W, et al. Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts. Nat Med 1998;4:1025–31.

    Google Scholar 

  30. Wolffenbuttel BHR, Crijns FRL, Huijberts MSP, Swennen GNM, Boulanger CM, Poitevin P et al. Breakers of advanced glycation end products restore large artery properties in experimental diabetes. Proc Natl Acad Sci U S A 1998;95:4630–4.

    Google Scholar 

  31. Vlassara H, Cai W, Crandall J, Goldberg T, Oberstein R, Dardaine V, et al. Inflammatory mediators are induced by dietary glycotoxins, a major risk factor for diabetic angiopathy. Proc Natl Acad Sci U S A 2002;99:15596–601.

    Google Scholar 

  32. Liuzzo G, Biasucci LM, Rebuzzi AG, Maseri A, Grillo RL, Gallimore JR, et al. The prognostic value of C-reactive protein and serum amyloid A protein in severe unstable angina. N Engl J Med 1994;331:417–24.

    Google Scholar 

  33. Mulder DJ, Water TV, Lutgers HL, Graaff R, Gans RO, Zijlstra F, et al. Skin autofluorescence, a novel marker for glycemic and oxidative stress-derived advanced glycation endproducts: an overview of current clinical studies, evidence, and limitations. Diabetes Technol Ther 2006;8:523–35.

    Google Scholar 

  34. Odetti P, Pronzato MA, Noberasco G, Cosso L, Traverso N, Cottalasso D, et al. Relationships between glycation and oxidation related fluorescences in rat collagen during aging. An in vivo and in vitro study. Lab Invest 1994;70:61–7.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. www.bsl.nl/shop/

    D. J. Mulder

Authors
  1. D. J. Mulder
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. P. L. van Haelst
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. R. Graaff
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. R. O. Gans
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. F. Zijlstra
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. A. J. Smit
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to D. J. Mulder.

Additional information

Department of Internal Medicine, University Medical Center Groningen, Groningen, the Netherlands

Department of Cardiology, Antonius Hospital, Sneek, the Netherlands

Department of Biomedical-Engineering, University Medical Center Groningen, Groningen, the Netherlands

Department of Internal Medicine, University Medical Center Groningen, Groningen, the Netherlands

Department of Cardiology, University Medical Center Groningen, Groningen, the Netherlands

Department of Internal Medicine, University Medical Center Groningen, Groningen, the Netherlands

D.J. Mulder Department of Internal Medicine, University Medical Center Groningen, PO Box 30.001, 9700 RB Groningen, the Netherlands

Rights and permissions

Reprints and permissions

About this article

Cite this article

Mulder, D.J., van Haelst, P.L., Graaff, R. et al. Skin autofluorescence is elevated in acute myocardial infarction and is associated with the one-year incidence of major adverse cardiac events. NHJL 17, 162–168 (2009). https://doi.org/10.1007/BF03086239

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03086239

Search

Navigation